Drug Profile

hOMSC 300

Alternative Names: hOMSC; hOMSC-300; human Oral Mucosa Stem Cells

Latest Information Update: 14 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CYTORA
Class Mesenchymal stem cell therapies; Stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Multiple system atrophy

Most Recent Events

14 Jan 2026 hOMSC 300 is still in phase I trials for Multiple system atrophy in Israel (Intratracheal, Injection)
28 Dec 2025 No recent reports of development identified for phase-I development in Multiple system atrophy in Israel (Intratracheal, Injection)
19 May 2025 Efficacy and adverse events data from phase-I trial in multiple system atrophy released by Cytora

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com